Loading
Latest filing published 26 Aug 2026 for 인바이오.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of 이명재 in 인바이오, where the filings describe the role as chief executive. The record holds 15 filings, for trades running from 14 November 2024 to 26 August 2026.
Every open-market trade on record is a purchase: 14 purchases worth €11k, and no sale. The totals exclude 13 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2026 to date brings 4 purchases and no sales.
On 26 August 2026 came the latest disclosure, a transaction in 인바이오. The last purchase on record was published on 18 August 2026, which is 68 days ago. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations